ABSCINT-HER2
HER2-positive cancers (e.g., Breast Cancer)
Phase 1/2Active
Key Facts
About Abscint
Abscint is pioneering a novel diagnostic approach in oncology through its platform for developing sdAb-based PET imaging tracers. The company's lead candidate, a 68Ga-labeled anti-HER2 tracer, is designed to illuminate HER2-positive metastases throughout the body, addressing critical unmet needs in patient selection, treatment monitoring, and biopsy guidance. Founded in 2019 and based in Leuven's biotech hub, Abscint is positioning its technology as a faster, safer, and more precise alternative to invasive biopsies and conventional imaging, with the potential to transform personalized cancer care.
View full company profile